ASCO 2009 - Randomized Trial of p53 Targeted Adjuvant Therapy for Patients with Organ-Confined Node-Negative Urothelial Bladder Cancer - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - Studies have suggested a prognostic role for p53 in patients with urothelial carcinoma (UC) of the bladder.
Login to read more...
|
ASCO 2009 - Failure of Initial VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma: What Next? - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - In this study, patient characteristics data on second-line therapies and outcomes were analyzed for patients with metastatic renal cell carcinoma (RCC) who received anti-VEGF therapy at seven centers.
Login to read more...
|
ASCO 2009 - A Multicenter Phase II Study of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Chemotherapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU-0475 - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - This study investigated the addition of bevacizumab to the standard regimen of cisplatin/gemcitabine as first-line therapy for patients with metastatic urothelial carcinoma (UC).
Login to read more...
|
ASCO 2009 - Independent Validation of the 2002 UICC TNM Staging System for Papillary Renal Cell Carcinoma in a Multicenter Cohort - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - The accuracy of the standard UICC TNM classification for predicting outcomes for patients with papillary renal cell carcinoma (pRCC) is unknown.
Login to read more...
|
ASCO 2009 - A Phase II Study of Sunitinib on a Continuous Dosing Schedule in Patients with Relapsed or Refractory Urothelial Carcinoma - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Sunitinib has demonstrated activity as a second-line agent for patients with advanced urothelial carcinoma (UC) when administered on a 4 week on, 2 week off schedule.
Login to read more...
|
ASCO 2009 - A Randomized, Double-Blind Phase III Study of Pazopanib in Treatment-Naive and Cytokine-Pretreated Patients with Advanced Renal Cell Carcinoma - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - In this study, the safety and efficacy of the oral multikinase angiogenesis inhibitor pazopanib was compared to placebo in patients with advance RCC.
Login to read more...
|
ASCO 2009 - Vascular Thromboembolic Events in Patients with Advanced Urothelial Cancer Treated with Carboplatin/Gemcitabine Alone or in Combination with Bevacizumab - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Cisplatin-based chemotherapy is the first-line agent for metastatic urothelial carcinoma (UC).
Login to read more...
|
ASCO 2009 - Adjuvant Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Little evidence exists regarding the use of adjuvant chemotherapy following radical nephroureterectomy for the management of patients with upper tract urothelial carcinoma (UTUC).
Login to read more...
|
ASCO 2009 - Final Results of the Phase III, Randomized, Double-Blind AVOREN Trial of First-Line Bevacizumab + Interferon-α2a in Metastatic Renal Cell Carcinoma - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - The authors reported the final results from the bevacizumab plus interferon vs. interferon alone trial for patients with metastatic renal cell carcinoma (mRCC).
Login to read more...
|
ASCO 2009 - Prognostic Risk Group Classification for Patients with Platinum-Refractory Metastatic Urothelial Cancer Treated with Second-Line Chemotherapy - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Second-line chemotherapy agents for patients with platinum-refractory metastatic urothelial cancer (UC) are associated with low response rated and short progression-free and overall survival rates.
Login to read more...
|
ASCO 2009 - Use of CA9 Gene Single Nucleotide Polymorphisms to Predict Prognosis and Treatment Response of Metastatic Renal Cell Carcinoma - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - This study investigated the role of single nucleotide polymorphisms (SNPs) and mutations of the CA9 gene with CAIX expression response to immunotherapy and survival.
Login to read more...
|
ASCO 2009 - Phase II Presurgical Study of Bevacizumab Plus Erlotinib in Untreated Patients with Metastatic Renal Cell Carcinoma - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - The objective of this study was to further define the safety and efficacy of bevacizumab therapy in patients with metastatic renal cell carcinoma (mRCC), prior to surgery.
Login to read more...
|
ASCO 2009 - VEGF Single Nucleotide Polymorphisms and Correlation to Sunitinib-Induced Hypertension in Metastatic Renal Cell Carcinoma Patients - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - The authors investigated the association among VEGF single nucleotide polymorphisms (SNPs) and the development of hypertension in metastatic RCC patients undergoing sunitinib treatment.
Login to read more...
|
ASCO 2009 - Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - The object of this study was to identify genetic markers in the pharmacokinetic and pharmacodynamic pathway of sunitinib that predispose patients to the development of toxicities.
Login to read more...
|
ASCO 2009 - Histopathology in Surgically Treated Renal Cell Carcinoma: Is There a Survival Difference when Stratified by Stage? - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - The object of this study was to determine the role of RCC histopathology on stage-specific survival rate in a population-based cohort.
Login to read more...
|
ASCO 2009 - A Nomogram Predicting Disease-Specific Survival after Nephrectomy for Papillary Renal Cell Carcinoma - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Most prognostic studies in RCC focus on patients with clear cell histology.
Login to read more...
|
ASCO 2009 - Macroscopic Versus Microscopic Vascular Tumour Invasion in Patients with Clear Cell Renal Cell Carcinoma: Does it Make a Difference? - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - This study evaluated the prognostic impact of macroscopic vs. microscopic vascular invasion on metastasis-free survival in patients with clear cell RCC.
Login to read more...
|
ASCO 2009 - Laparoscopic Renal Cryoablation: Risk Factor Analysis to Predict Oncologic Outcomes with Minimum 5-Year Follow-Up - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Ablation therapy is becoming an increasingly popular alternative for patients with renal masses.
Login to read more...
|
ASCO 2009 - Association of Percentage of Tumor Burden Removed with Debulking Nephrectomy and Progression-Free Survival in Metastatic Renal Cell Carcinoma Patients Treated with VEGF-Targeted Therapy - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Cytoreductive nephrectomy is the standard of care for good performance patients with metastatic RCC.
Login to read more...
|
ASCO 2009 - Sunitinib in Patients with Unresectable Primary Renal Cell Carcinoma - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - In this study, the ability of sunitinib to shrink unresectable metastatic RCC was evaluated.
Login to read more...
|
ASCO 2009 - Efficacy and Toxicity of Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Severe Renal Impairment or on Haemodialysis - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - The authors investigated the efficacy and toxicity of sunitinib in patients with metastatic RCC and severe renal insufficiency.
Login to read more...
|
Conference Coverage 
